A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer

Timeline

Start

2020-11-10

Primary completion

2023-07-15

Completion

2025-03-01

Publications

• Pan Y, Yang X, Zhou Q, Zhao Y, Han G, Pang Q, Zhang Z, Wang Q, Yao J, Wang H, Yang W, Liu B, Chen Q, Du X, Cai K, Li B, Huang Y, Li X, Jia Y, Song L, Shi W, Wu YL. Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-beta bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial. Signal Transduct Target Ther. 2026 Jun 16;11(1):239. doi: 10.1038/s41392-026-02779-1.

Drugs

Indications